|
EQS-News: Drägerwerk AG & Co. KGaA / Key word(s): Miscellaneous Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052 of the Commission 22.11.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052 of the Commission: Extension of the share buyback for the employee stock program On September 2, 2024, the Executive Board of Drägerwerk Verwaltungs AG had resolved a share buyback for the employee stock program of Drägerwerk AG & Co. KGaA (“Company”). Accordingly, the Company was to buy back up to 676,000 of its own preferred shares on the stock exchange in the period from October 7 to probably November 18, 2024. This period has now been extended until probably March 2025. In all other respects, the provisions of the announcement of October 1, 2024, on the announcement of the share buyback apply. By November 21, 2024, the Company has acquired 27,977 of its own preferred shares for the employee stock program. By the end of the buyback period, the Company will buy back 49,339 of its own preferred shares. Lübeck, Germany, November 22, 2024 Executive Board Moislinger Allee 53–55 22.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Updated: Eli Lilly expects FDA decision on Alzheimer’s drug by end of year as it unveils full PhIII data
Eli Lilly said Monday morning that it has submitted an application for its experimental Alzheimer’s drug donanemab to the FDA, and expects a decision by
July 18, 2023